Prof. Yvonne Dei-Adomako MBBS, FWACP

Dr. Yvonne Dei-Adomakoh has over twenty-three (23) years of medical practice. She is currently a Consultant Haematologist at Korle-bu Teaching hospital and a Senior Lecturer at the Department of Haematology, University of Ghana Medical School. As a Haematologist, she treats patients with leukaemia, lymphoma, multiple myeloma, and benign haematological diseases such as sickle cell disease and other inherited and acquired anaemias.

In addition, as a Senior lecturer at the University of Ghana Medical School, she teaches undergraduates and MPhil students; she has presented numerous research papers both locally and at international conferences and has published several peer-reviewed articles in local and international journals.

She holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the College of Health Sciences University of Maiduguri, Borno State, Nigeria and a Specialist postgraduate training in Laboratory Medicine (Specializing in Haematology) from the West African College of Physicians.

In 2004 and 2014, she was awarded a UNDP sponsored fellowship at the Haematological Malignancies Diagnostic Centre, Leeds, United Kingdom and the VIRDE (Vanderbilt Institute of Research Development and Ethics) Doris Duke Fellowship award, Nashville, U.S.A respectively. In addition, she is a fellow of the West African College of Physicians, member of the Ghana Medical Association, American Society of Haematology and Ghana Society of Haematology, among others.

Dr Dei-Adomakoh serves on many boards and committees in the Medical school, College of Health Sciences, and the Korle-Bu Teaching Hospital. She is also a founding executive member of the Leukemia Project Foundation. This non-profit organization is involved in caring for patients living with blood cancer and sickle cell disease.

She is currently the principal investigator for a National Institute of Health-funded project titled BLOODSAFE: “Development and evaluation of community-based approaches and donor care intervention models for improving availability and safety of blood for the management of severe anaemia in Ghana” and A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)”.

Courses